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Skin autofluorescence predicts major 
adverse cardiovascular events in patients 
with type 1 diabetes: a 7‑year follow‑up study
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Abstract 
Background: Advanced glycation end‑products play a role in diabetic vascular complications. Their optical proper‑
ties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searched for an 
association between SAF and major adverse cardiovascular events (MACE) incidence in subjects with Type 1 Diabetes 
(T1D) during a 7 year follow‑up.
Methods: During year 2009, 232 subjects with T1D were included. SAF measurement, clinical [age, sex, body mass 
index (BMI), comorbidities] and biological data (HbA1C, blood lipids, renal parameters) were recorded. MACE (myo‑
cardial infarction, stroke, lower extremity amputation or a revascularization procedure) were registered at visits in the 
center or by phone call to general practitioners until 2016.
Results: The participants were mainly men (59.5%), 51.5 ± 16.7 years old, with BMI 25.0 ± 4.1 kg/m2, diabetes dura‑
tion 21.5 ± 13.6 years, HbA1C 7.6 ± 1.1%. LDL cholesterol was 1.04 ± 0.29 g/L, estimated Glomerular Filtration Rates 
(CKD‑EPI): 86.3 ± 26.6 ml/min/1.73 m2. Among these subjects, 25.1% were smokers, 45.3% had arterial hypertension, 
15.9% had elevated AER (≥ 30 mg/24 h), and 9.9% subjects had a history of previous MACE. From 2009 to 2016, 22 
patients had at least one new MACE: 6 myocardial infarctions, 1 lower limb amputation, 15 revascularization proce‑
dures. Their SAF was 2.63 ± 0.73 arbitrary units (AU) vs 2.08 ± 0.54 for other patients (p = 0.002). Using Cox‑model, after 
adjustment for age (as the scale time), sex, diabetes duration, BMI, hypertension, smoking status, albumin excretion 
rates, statin treatment and a previous history of MACE, higher baseline levels of SAF were significantly associated with 
an increased risk of MACE during follow‑up (HR = 4.13 [1.30–13.07]; p = 0.02 for 1 AU of SAF) and Kaplan–Meier curve 
follow‑up showed significantly more frequent MACE in group with SAF upper the median (p = 0.001).
Conclusion: A high SAF predicts MACE in patients with T1D.
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Introduction
Despite the decline of cardiovascular disease in patients 
with type 1 diabetes (T1D) [1], it remains by far the first 
cause of mortality, as recently reported in patients with 
long duration of diabetes [2], and a major concern even 
in children who often present features of subclinical 
cardiovascular disease [3]. The cardiovascular risk of sub-
jects with T1D is influenced by modifiable conventional 
risk factors such as arterial hypertension, dyslipidemia, 
and smoking, [4], and is strongly higher in the presence 
of diabetic nephropathy [5], but hyperglycaemia by itself 
is thought to play an important role.
Long-term hyperglycaemia promotes cardiovascu-
lar mortality, with a gradual increase of hazard ratios for 
death among patients with T1D compared to non diabetic 
subjects according to the HbA1C levels [6]. However a risk 
persists for well-controlled subjects with HbA1C ≤ 6.9%. 
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The effect of intensive glucose control on cardiovascu-
lar events was significant only 11 years after the intensive 
glucose control intervention in the Diabetes Control and 
Complications Trial, owing to a “glucose memory” effect 
[7]. A recent detailed analysis of cardiovascular risk factors 
of the DCCT-EDIC participants emphasized the impor-
tance of the mean time-weighted HbA1C [8].
Advanced glycation end-products (AGEs) generated 
from excess glucose have deleterious effects on endothe-
lial cells [9]. They are thought to contribute to the mem-
ory of hyperglycaemia [10]. The skin concentrations of 
AGEs have been related to the progression of intima-
media thickness in the DCCT-EDIC study [11]. Due to 
their fluorescent properties, the accumulation of AGEs 
in tissues can be simply estimated by measuring the skin 
autofluorescence (SAF) [12]. SAF predicted later car-
diovascular events in patients with type 2 diabetes [13]. 
We have related it to later impaired renal function [14] 
and neuropathy [15] in patients with T1D. However, the 
relation between SAF and later cardiovascular events 
has not been reported yet in T1D. We aimed to test the 
association between SAF and future occurrence of major 
adverse cardiovascular event (MACE) in patients with 
T1D followed-up over 7 years.
Subjects and methods
Design and patients
Two hundred and thirty-two patients with T1D were 
included consecutively in 2009 after consent during annual 
visit in University Hospital of Bordeaux. The only exclusion 
criterion was ultraviolet reflectance < 10% that precluded 
the measurement of SAF. The patients with skin photo-
types V and VI were therefore not included. The following 
data were recorded at inclusion on the day of SAF meas-
urement: age, sex, body mass index, duration of diabetes, 
treatment by Continuous Subcutaneous Insulin Infusion, 
arterial hypertension (blood pressure ≥ 140/90  mmHg 
and/or treatment with antihypertensive drug), treatment 
by statins, previous macrovascular events, and smoking 
history. The biological data recorded included HbA1c lev-
els, blood lipids, the Albumin Excretion Rates (AER), and 
serum creatinine to estimate the Glomerular Filtration 
Rates calculated with the CKD-EPI formula [16]. Partici-
pants were prospectively followed-up until the occurrence 
of new cases of major adverse cardiovascular events 
(MACE) till March 2017. Number of patients was men-
tioned when data were missing.
Skin autofluorescence (SAF)
The accumulation of AGEs was evaluated at inclusion 
[12], using the AGE-Reader (diagnOptics BV, Gronin-
gen, The Netherlands). The device illuminated 1  cm2 of 
the forearm skin. SAF values were calculated by dividing 
the mean emitted light intensity (excitation light source 
ranging from 300 to 420 nm) by the mean reflected exci-
tation light intensity from the skin (over 300–420  nm). 
The patients with Fitzpatrick phototypes V and VI were 
not included due to their skin pigmentation, which had 
ultraviolet reflectance of < 10%. The results were the 
mean of three consecutive measurements of SAF and 
were expressed in arbitrary units (AU).
Outcomes
MACE were defined as myocardial infarction, stroke, 
lower limb amputation, or a revascularization procedure 
for coronary, carotid or lower limb arteries. Every year, 
patients came in visit at hospital, MACE was collected by 
physician if occurred since previous visit and recorded in 
the informatic medical folder of each patient. If we had 
no recent news we called practitioner to ask if MACE or 
death occurred.
Statistical methods
The results are presented as mean ± SD for continuous 
variables, or median (IQR) for those with skewed distri-
bution. Categorial variables are presented as numbers 
(percentages). A Cox model with delayed entry (taking 
age as the scale-time) was used to investigate the associa-
tion between SAF and MACE. R2 of the model has been 
calculated by the following formula: R2 = 1 − e − (LRT/n), 
where LRT is the likelihood-ratio statistic. Log-linearity 
of the model has been tested using SAF as a continuous 
variable and in quartile. Risk proportionality has been 
verified both by testing the interaction between SAF and 
time and by using Schoenfeld residuals. In a first step, 
analyses were performed to test the association between 
each co-variable and MACE in order to select variables 
for the multivariate analysis. Then, all the variables asso-
ciated with MACE with a p value ≤ 0.10 were retained in 
the multivariate Cox model. All statistical analyses were 
performed using SAS version 9.3 (SAS Institute Inc, Cary, 
NC) and results were considered significant when p < 0.05. 
Follow-up was analysed using Kaplan–Meier curve.
Results
Characteristics of the population at inclusion
Participants were mainly men (59.5%), 51.5 ± 16.7  years 
old, with a 21.5 ± 13.6  years diabetes duration. Their 
BMI was 25.0 ± 4.1 kg/m2, HbA1c 7.6 ± 1.1%, eGFR was 
86.0 ± 26.3  ml/min/1.73  m2. Among them, 25.1% were 
smokers, 45.3% had arterial hypertension, 15.9% had 
elevated AER (≥ 30 mg/24H), and 9.9% had a history of 
previous macrovascular event. Their SAF was 2.13 ± 0.58 
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AU. The scatterplot for SAF over age is presented as a 
Additional file 1: Figure S1.
Subjects with new major adverse cardiovascular events 
during the follow‑up
Twenty-two patients presented MACE during a median 
(IQR) duration of follow-up of 7.8 [7.6–8.0] years: 6 
myocardial infarctions, 1 gangrene and 15 revascu-
larization procedures. As compared to subjects with-
out MACE, they were significantly more men, 10  years 
older, with 9 more years of diabetes duration, but similar 
HbA1c (Table  1). The lipid profiles did not significantly 
differ, but subjects with MACE were more likely to be 
treated by statins in comparison with subjects without 
MACE. Arterial hypertension, abnormal eGFR (< 60 ml/
min/1.73 m2) and abnormal (> 30 mg/24 h) AER were sig-
nificantly more frequent.
SAF and new major adverse cardiovascular events (Table 2, 
Fig. 1)
At inclusion, the SAF was 2.63 ± 0.73 AU in patients who 
presented MACE during the follow-up, vs 2.08 ± 0.54 
for the others (p = 0.002). In addition to SAF, gender, 
duration of diabetes, BMI, hypertension, use of statins, 
smoking, renal parameters, and previous MACE were 
associated with MACE during the follow-up at a p 
value ≤ 0.10 and were retained in the multivariate anal-
ysis. SAF high level in 2009 was associated with signifi-
cant increased risk of MACE during the 7 next years: 
HR  =  4.13 [1.30;13.07] for increasing of +1 SAF AU 
(p = 0.02). Elevated hazard ratio for sex, MACE at base-
line, BMI, statins treatment, abnormal eGFR, albumin 
excretion rates, hypertension and diabetes duration were 
not significantly associated with MACE. Using Kaplan–
Meier curve, the follow-up of patients categorized in two 
groups according to SAF median (< 2.0 vs ≥ 2.0) showed 
that patients with high SAF more frequently devel-
oped MACE than those with SAF lower than median 
(p = 0.001). R2 of the model was estimated at 19%.
Discussion
Higher SAF measured in 2009 was associated with 
increased risk of later cardiovascular events (HR: 4.13, 
CI 95%: 1.30–13.07) after adjusting for diabetes duration, 
arterial hypertension, treatment by statins, renal param-
eters and previous cardiovascular events. SAF therefore 
appears as a significant predictor of cardiovascular events 
in Type 1 Diabetes. Participants with DT1 who experi-
enced a cardiovascular event during the 7  years follow-
up were older, with a 9  years longer diabetes duration, 
but similar HbA1C as compared to the others. They had 
Table 1 Characteristics of participants at baseline 
according to the incidence of major adverse 
cardiovascular event over the 7-year follow-up
Data presented in N (%) and mean ± standard deviation
p value: COX test for qualitative variables and quantitative variables
Major cardiovascular event
No (N = 210) Yes (N = 22) p
Age (years) 50.54 ± 16.76 60.56 ± 13.30 0.007
Sex men 121 (57.6) 17 (77.2) 0.07
BMI (kg/m2) 24.7 ± 3.7 27.1 ± 6.3 0.09
Diabetes duration (years) 20.6 ± 12.8 29.6 ± 17.8 0.03
HbA1c (mmol/ml) in 2009 (%) 7.6 ± 1.0 7.5 ± 1.0 0.74
Insulin pump 40 (19.0) 5 (22.7) 0.77
Smoking habits (n = 219) 51 (25.8) 4 (18.1) 0.43
HDL (g/l) (n = 222) 0.64 ± 0.19 0.58 ± 0.17 0.17
LDL (g/l) (n =t221) 1.03 ± 0.29 1.04 ± 0.33 0.88
Triglycerides (g/l) (n = 205) 0.89 ± 0.63 1.11 ± 0.53 0.13
Statin at baseline (n = 222) 45 (22.5) 13 (59.0) 0.0002
Hypertension 87 (41.43) 18 (81.82) 0.0003
Previous history of MACE 13 (6.19) 10 (45.45) < 0.0001
eGFR (mL/min) (n = 225)
 ≥ 60 179 (88.18) 13 (59.09) 0.001
 < 60 24 (11.82) 9 (40.91)
Albumin excretion rate (mg/24 h) (n = 227)
 < 30 179 (86.89) 12 (57.14) 0.002
 ≥ 30 27 (13.11) 9 (42.86)
 SAF (AU) 2.08 (0.54) 2.63 (0.73) 0.002
Table 2 Risk of major adverse cardiovascular event 
over the follow-up according to SAF at baseline
Cox multivariate analysis (n = 205, 21 events)
HR 95% Confidence 
interval
p
SAF (per 1 AU) 4.13 1.30; 13.07 0.02
Sex
 Men 4.15 0.87; 19.77 0.07
BMI (per 1 kg/m2) 1.11 0.96; 1.27 0.16
MACE at baseline
 Yes 3.01 0.99; 9.08 0.05
Statins baseline
 Yes 2.55 0.77; 8.47 0.13
eGFR (mL/min)
  < 60 1.54 0.32; 7.31 0.59
Albumin excretion rate (mg/24 h)
  ≥ 30 1.92 0.54; 6.88 0.32
Hypertension
 Yes 2.70 0.61; 11.98 0.19
 Diabetes duration in 2009 
(per 1 year)
1.02 0.98; 1.06 0.38
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more arterial hypertension, more dyslipidemia accord-
ing to similar blood lipids despite twice more treated by 
statins, more frequent abnormal albumin excretion and 
estimated glomerular filtration rates, and more previous 
cardiovascular events. Their SAF were + 30% higher.
SAF to predict MACE
The prediction of cardiovascular events by SAF has 
already been reported in other diseases, as HIV infec-
tion [16] and Chronic Kidney Diseases although signifi-
cance was lost (p = 0.09) after multivariate adjustments 
[17]. In type 2 diabetes, Lutgers et al. have shown that a 
high SAF (upper than median) was related to the 3 years 
cardiovascular prognosis, adjusted to the UKPDS risk 
score [13]. For Type 1 Diabetes, cross-sectional studies 
have reported relationship between SAF or skin intrin-
sic fluorescence and coronary calcifications [18], and 
clinical history of coronary heart disease [19]. But no 
prospective study had shown that SAF could predict car-
diovascular events. In our previous analysis on the same 
cohort with a shorter follow-up of only 4 years [14], SAF 
predicted later eGFR impairement and later MACE: 
OR 4.84 (1.31–17.89), but the relation with later MACE 
did not reach significance with adjustment for previ-
ous MACE: OR 2.98 (0.77–11.47). However, this previ-
ous analysis was based on lower cases of cardio-vascular 
events. Three years later, the relation between SAF keeps 
significant after this adjustment: OR 4.13 (1.30–13.07). 
The longer follow-up with higher numbers of events now 
allows to reach significance for the prediction of macro-
vascular events in our patients independently from clas-
sical risk factors.
The role of AGEs
The main mechanism underlying this prediction is the 
deleterious effect of AGEs on the vascular system [9]. 
Previous studies found that serum levels of advanced 
glycation end-products-modified LDL [20], and Methyl-
glyoxal [21] were related to later cardiovascular events or 
to the progression of atherosclerosis as reflected by the 
carotid intima-media thickness, in type 1 diabetes. AGEs 
are generated inside peripheral cells before they are liber-
ated in the extracellular space [9]. Their accumulation in 
tissues as estimated by SAF is expected to better reflect 
their influence, than their circulating levels. SAF has been 
Fig. 1 MACE during follow‑up according to SAF median in patients with SAF < 2.0 and patients with SAF 2.0. p = 0.001
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related to cardiac tissue glycation [22], inappropriate left 
ventricular mass and diastolic dysfunction [23], long 
wavelenght-1 and sublinical markers as the intima-media 
thickness [24] and it is increased in patients with an 
abdominal aortic aneurysm [25]. The skin concentrations 
of AGEs have been related to coronary calcifications, 
left ventricular masses and progression of intima-media 
thickness in the DCCT-EDIC study [11]. SAF was related 
to the age of the participants (ß = + 0.397; p < 0.001) 
which is very similar to reports from other groups in 
participants with T1D [26–28]. Although an indirect 
estimation of the accumulation of AGEs, SAF has some 
advantages on skin biopsies: low cost, simplicity, non-
invasiveness, and repeatability.
SAF and metabolic memory
The SAF may predict macrovascular events because it is 
a marker of the metabolic memory of hyperglycaemia, 
which seems critical for macroangiopathy in T1D. The 
cardiovascular benefits of the intensive glucose control 
during the DCCT came apparent only later, 11 years after 
the end of its active phase [7], which led to propose the 
concept of glucose memory. This concept is also sup-
ported by the long-term results of the UKPDS for type 
2 diabetes. A recent analysis of the risk factors for car-
diovascular disease in the DCCT-EDIC participants has 
emphasized the major role of their mean time-weighted 
HbA1C, second only to age [8]. Previous studies have 
reported that SAF relates to the HbA1C of the previ-
ous years, better than to the present HbA1C in T1D 
[27, 29–31]. In elderly participants of the 3-City cohort 
study from the general population, we have shown that 
SAF relates to glycaemia and HbA1C measured ten years 
before, rather than to their values measured at the same 
time as SAF [32]. Most of the associations between skin 
intrinsic fluorescence and T1D complications lost sig-
nificance after adjustment to the mean HbA1C over time 
for the DCCT participants [33]. The association between 
skin fluorescence and coronary arterial calcifications was 
however still significant after this adjustment, arguing for 
an additional value of the fluorescence measurement. But 
no prospective study had shown that SAF could predict 
cardiovascular events. In our previous analysis on the 
same cohort with a shorter follow-up of only 4 years [14], 
SAF predicted later eGFR impairement and later MACE: 
OR 4.84 (1.31–17.89), but the relation with later MACE 
did not reach significance with adjustment for previ-
ous MACE: OR 2.98 (0.77–11.47). Three years later, the 
relation between SAF keeps significant after this adjust-
ment: OR 4.13 (1.30–13.07). In the real life, the history 
of HbA1C is often not complete for many T1D patients, 
and death from cardiovascular causes are thrice more 
frequent even for the best controlled (HbA1C ≤ 6.9%) 
according to the Swedish register [6]. This underlines the 
interest of a metabolic memory marker that predicts car-
diac events.
Others factors
Hyperglycaemia-related mechanisms may not be the only 
explanation for the relationship between SAF and mac-
rovascular diseases. SAF increases with age, the strong-
est risk factor for cardiovascular events in T1D [8]. SAF 
has recently been related to the components of the meta-
bolic syndrome [34], especially low HDL-cholesterol and 
arterial hypertension [35], that increasingly mediate the 
effect of glucose control on cardiovascular risk in aging 
T1D [5]. The progression of SAF in our patients with 
T1D highly depends on their glomerular filtration rates 
[15], as expected because renal insufficiency reduces the 
clearance of AGEs. This effect probably worsens as SAF 
predicts the impairment of GFR in T1D [14]. Diabetic 
nephropathy is a well-known, major contributor to car-
diovascular disease in T1D [36]. But the relation between 
SAF and cardiovascular events reported in our study, was 
still significant after adjusting for age, arterial hyperten-
sion, blood lipids and renal parameters.
Limitations
Some other hypothesis can however not be excluded on 
the basis of our study, which can be considered as limi-
tations. We have recently shown that SAF quickly rises 
during acute renal failure [37]. That is a powerful predic-
tor of major cardiovascular events in type 2 diabetes [38], 
but to our knowledge this has not been reported for T1D. 
We also found that SAF progressed less in our patients 
whose T1D was treated by continuous subcutaneous 
insulin infusion CSII [15], which has been related to less 
cardiovascular mortality [39]. This suggests that glycae-
mic variability may play a role in the accumulation of 
AGEs: even transient pikes of hyperglycaemia may have 
deleterious effects on vascular cells [10]. Long-term gly-
cemic variability has been related to a twice-higher risk of 
cardiovascular events in T1D [40]. Skin autofluorescence 
is however not influenced by short-term glycemic varia-
tions [41]. Finally, some reports have related SAF to phys-
ical activity indexes: aerobic exercise capacity, muscle 
strength [42], and regular performance of physical activi-
ties [43, 44], which has been related to less cardiovascular 
events in the FinnDiane cohort [45]. Some practical limi-
tations must also be mentioned. According to French law, 
we did not categorize the participants according to their 
ethnicity, but some subjects were excluded due to their 
skin pigmentation as already mentioned. The measure-
ment of SAF were performed on intact skin, but we can 
not rule out that some subjects might have applied some 
body lotions locally. Draelos et al. applied a topical AGE 
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inhibitor (blueberry extract) on the skin of 20 women 
with diabetes during three months, and they did not 
report any change of their SAF on this time interval [46]. 
An important proportion of the variability of SAF is not 
explained by age and usual covariates, some studies have 
suggested that genetic [47] or dietary factors may play a 
role, as diet is a source of AGEs [48]. Smoking has been 
related to SAF [35] and the relation between SAF and 
MACE was adjusted for tobacco use in our study, but we 
did not collect detailed dietary informations, so we can 
not exclude the role of some specific diet components, 
like coffee [35].
Conclusion
SAF seems to be a good mean to predict MACE in T1D. 
Further works are now required to explore these hypoth-
esis with more long term follow-up because fortunately 
only a few MACE occurred, a multicentric study with 
more patients is required to find strategies to slower the 
progression of SAF in T1D.
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